Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834651 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
A Phase 2 study, sponsored by Edwin Posadas, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01834651 is a Phase 2 study that has completed, run by Edwin Posadas, MD. The registered enrollment target is 17 participants.
The verdict
NCT01834651, a Phase 2 study, has completed, sponsored by Edwin Posadas, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant prostate cancer.
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-04-30 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834651
The ClinicalTrials.gov registry entry for NCT01834651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwin Posadas, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT01834651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834651 about?
NCT01834651 is a clinical study titled "A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases". This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate can...
What is the current status of trial NCT01834651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2013-04-30. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT01834651?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01834651?
This trial is sponsored by Edwin Posadas, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.